Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV000681651 | SCV000809098 | uncertain significance | Infantile cerebellar-retinal degeneration | 2018-07-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001868309 | SCV002131113 | uncertain significance | not provided | 2022-06-13 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies have shown that this missense change affects ACO2 function (PMID: 30689204). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ACO2 protein function. ClinVar contains an entry for this variant (Variation ID: 562210). This missense change has been observed in individual(s) with clinical features of ACO2-related conditions (PMID: 30689204, 32519519). This variant is present in population databases (rs768950391, gnomAD 0.01%). This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 684 of the ACO2 protein (p.Arg684Trp). |
Fulgent Genetics, |
RCV002485573 | SCV002792438 | uncertain significance | Infantile cerebellar-retinal degeneration; Optic atrophy 9 | 2022-03-01 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000681651 | SCV001432775 | pathogenic | Infantile cerebellar-retinal degeneration | 2020-09-16 | no assertion criteria provided | literature only |